UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/657,910	09/09/2003	Kenichi Chiba	EISN-018CP	5169
959 7590 05/21/2009 LAHIVE & COCKFIELD, LLP FLOOR 30, SUITE 3000			EXAMINER	
			OH, TAYLOR V	
ONE POST OFFICE SQUARE BOSTON, MA 02109			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			05/21/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

It is noted that applicants have filed an Amendment after the Final Rejection on 5/07/09; applicants' attorney has addressed the issues of record. The proposed amendment will be not entered because the amendment raises a new issue that would require further consideration and /or search; thus, it is not in a condition for allowance.

The Status of Claims

Claims 1-24,27-31,33,36,38-40,42-43,46-60,62-63,65-67 are pending.

Claims 1-24,27-31,33,62-63, and 65-67 are objected.

Claims 36, 38-40,42-43,46-60 are withdrawn from consideration.

Claim Objections

In claims 1, 2, 14, and their corresponding dependent claims, the phrase "

Y is CHR₁₉, C=0, or CR₁₉; and Z is CHR₁₈, C=0, or CR₁₈," is recited. The variables Y and Z contain not only a carbon group, but also a carbonyl group; the carbonyl group does not belong to the Group IV; therefore, it must be removed from the claims.

New Issue

In the proposed amendment, claims 71-72, 84, and their corresponding dependent claims, the variables Y and Z contain not only a carbon group, but a carbonyl group; the carbonyl group

Application/Control Number: 10/657,910 Page 3

Art Unit: 1625

does not belong to the Group IV. This raises a new issue that would require further consideration and /or search.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

The rejection of Claims 1-24,27-31,33,62-63, and 65-67 provisionally on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-22,40,43,66, and 81 of copending Application No. 10/507,067 has been withdrawn due to filing the Terminal Disclaimer on 5/07/09.

Applicants' Argument

- 1. Applicants argue the following issues:
 - i. Applicants request for rejoinder of withdrawn claims 46-60 and 95-109 because Group

IV is drawn to a pharmaceutical composition wherein X is oxygen, Y and Z are carbon

present a search burden.

Page 4

Applicants' arguments have been noted, but the arguments are not found to be persuasive.

Regarding the applicants' argument, the Examiner has noted applicants' argument. However, in claims 1, 2, 14, 46-60,71-72, 84, 95-109 and their corresponding dependent claims, the variables Y and Z contain not only a carbon group, but also a carbonyl group; the carbonyl group does not belong to the Group IV; furthermore, particularly claim 105(withdrawn-new) does contain the substituent R₉, which has the following species:

morpholine, intidazole, aminopyridine, or any one of:

In view of these groups, searching each group presents a lot of burdens for the examiner; also, unlike applicants remarks, there is no a single and inventive concept among them.

Therefore, it is improper to consider rejoining the withdrawn claims 46-60 and 95-109 to the current claims at this time. It would be better to cancel the withdrawn claims and any new claims related to the withdrawn claims in order to expedite the application.

Art Unit: 1625

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taylor Victor Oh whose telephone number is 571-272-0689. The

examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Janet Andres can be reached on 571-272-0867. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Taylor Victor Oh, MSD,LAC

Primary Examiner

Art Unit: 1625

/Taylor Victor Oh/

Primary Examiner, Art Unit 1625

5/19/09

Application/Control Number: 10/657,910

Page 6

Art Unit: 1625